South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck is gearing up to showcase its promising HIV research at the International AIDS Society Conference in Kigali. This ...

Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

This study is among the first to provide detailed data on DRM and VL among key populations (KPs), contributing significant value to HIV research and supporting reforms in the National AIDS/STD ...